Divi’s Laboratories Limited is a Company limited by shares, incorporated and domiciled in India. The Company is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management. The Company is a public limited company and the Company’s equity shares are listed in BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) in India.

Business area of the company

The Company manufactures Generic APIs, Nutraceutical Ingredients and offers Custom Synthesis of APIs to Big Pharma providing a competitive advantage over the entire life cycle of the products.

Divi's Laboratories Ltd.

Cipla Ltd.

Dr. Reddy's Laboratories Ltd.

Torrent Pharmaceuticals Ltd.

Abbott India Ltd.

Zydus Lifesciences Ltd.

Alkem Laboratories Ltd.

Lupin Ltd.

Biocon Ltd.

Gland Pharma Ltd.

Aurobindo Pharma Ltd.

Glaxosmithkline Pharmaceuticals Ltd.

Laurus Labs Ltd.

Ipca Laboratories Ltd.

Piramal Enterprises Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	88,587 Cr		EPS	111.8		High	3358.85
Stock P/E	29.8		Net Profit Margin	26.6		Low	3328

Market Cap	88,587 Cr	ROE	28.2%
P/E Ratio(TTM)	29.8	EPS(TTM)	117.0
P/B Ratio	7.3	Dividend Yield	0.9%
Industry P/E	65.2	Book Value	454.8
		Face Value	2.0

DIVISLAB